Neurogene (NGNE) Cash from Investing Activities (2013 - 2026)

Neurogene's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at $46.2 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 202.65% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (up 152.58% YoY) and the FY2025 annual result came in at $14.0 million, up 111.18% from the prior year.
• Cash from Investing Activities was $46.2 million for Q1 2026 at Neurogene, up from $29.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $65.4 million in Q4 2022 and bottomed at -$102.6 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$82000.0 in 2023 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 103324.14% in 2024, while the deepest fall reached 35224.39% in 2024.
• Neurogene's Cash from Investing Activities stood at $65.4 million in 2022, then slumped by 60.49% to $25.8 million in 2023, then tumbled by 497.27% to -$102.6 million in 2024, then jumped by 128.85% to $29.6 million in 2025, then surged by 56.17% to $46.2 million in 2026.
• Business Quant data shows NGNE's Cash from Investing Activities at $46.2 million in Q1 2026, $29.6 million in Q4 2025, and $22.0 million in Q3 2025.